| Drug Name | Pembrolizumab |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
Safety communication
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Optic neuritis |
| safety communication |
|